{"entity":{"id":"nct02758951","kind":"trial","name":"Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases","aka":["CAIRO6"],"tldr":"A phase 2/3 trial in colorectal cancer, run by Koen Rovers, active but no longer recruiting.","summary":"Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases is a phase 2/3, randomised interventional study registered as NCT02758951 by Koen Rovers, with a registry enrolment figure of 358 participants, started 2017-06-01 and due to reach its primary completion in 2024-10-31. Interventions recorded: Perioperative systemic therapy; Perioperative CAPOX-bevacizumab; Perioperative FOLFOX-bevacizumab; Perioperative FOLFIRI-bevacizumab; CRS-HIPEC, experimental arm; CRS-HIPEC, control arm. Conditions listed: Colorectal Neoplasm; Colorectal Cancer; Colorectal Neoplasms Malignant; Colorectal Carcinoma; Colorectal Adenocarcinoma; Peritoneal Neoplasms; Peritoneal Carcinomatosis; Peritoneal Cancer; Peritoneal Metastases; Peritoneal Neoplasm Malignant Secondary Carcinomatosis; Peritoneal Neoplasm Malignant Secondary. Primary outcome: Overall survival. Colorectal eligibility wording from the registry: \"* histological or cytological proof of PM of a non-appendiceal colorectal adenocarcinoma with ≤50% of the tumour cells being signet ring cells;\". Sites: Belgium, Netherlands. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT02758951","url":"https://clinicaltrials.gov/study/NCT02758951"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["hipec"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02758951","phase":"2/3","setting":"Perioperative Systemic Therapy and Cytoreductive Surgery With HIPEC Versus Upfront Cytoreductive Surgery With HIPEC Alone for Isolated Resectable Colorectal Peritoneal Metastases: a Multicentre, Open-label, Parallel-group, Phase II-III, Randomised Superiority Study","sponsor":"Koen Rovers","enrolled":358,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02758951/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"hipec","kind":"technology","name":"HIPEC / PIPAC (intraperitoneal chemotherapy)","route":"/technologies/hipec/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}